Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persistent asthma. BioSim™ Omalizumab ELISA kit has been developed for specific quantification of Omalizumab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Omalizumab in human serum and plasma.
• Detection Range: 10 - 1000 ng/ml
• Sensitivity: 10 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®), bevacizumab (Avastin®), trastuzumab(Herceptin®)
